grant

Molecular markers of phenotype, therapeutic responsiveness and prognosis in human cancers. [ 2009 - 2013 ]

Also known as: Improving characterisation of human cancers in order to optimise clinical management and treatment

Funded by National Health and Medical Research Council
Managed by Garvan Institute of Medical Research
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/535903]

Researchers: Prof Roger Daly (Principal investigator) ,  A/Pr Ewan Millar ,  Prof Andrew Biankin ,  Prof Christopher Ormandy ,  Prof Elizabeth Musgrove
View all 9 related researchers

Brief description This proposal aims to identify molecular markers that can be used to classify subtypes of particular cancers according to their prognosis and response to therapy. This will optimise selection of patients for the most appropriate treatment and lead to the development of new therapeutic strategies.

Funding Amount $AUD 11,762,116.79

Funding Scheme Programs

Notes Program Grant

Click to explore relationships graph
Help

Related Publications

  • Associated with Clinical and molecular characterization of HER2 amplified-pancreatic cancer
    handle : 2440/94922
  • Associated with Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies
    handle : 2440/61879
  • Associated with qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles
    handle : 2440/97116

Related Organisations

Related People

Subjects
321015 | Breast Cancer, Prostate Cancer | Cancer and related disorders, Molecular Oncology | Cancer: mechanisms of growth, invasion, metastases | Pancreatic Cancer | Prognostic Markers |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA